Blocklisting Six Monthly Return

London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:

1. Name of applicant: Hutchison China MediTech Limited

2. Name of scheme: (a) Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2005 (“2005 HCML Share Option Scheme”)

   (b) Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2015 (“2015 HCML Share Option Scheme”)

3. Period of return: From June 29, 2018 to December 28, 2018

4. Balance under scheme from previous return: (a) 2005 HCML Share Option Scheme: 219,353 ordinary shares of US$1 each

   (b) 2015 HCML Share Option Scheme: 2,425,597 ordinary shares of US$1 each

5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: (a) 2005 HCML Share Option Scheme: Nil

   (b) 2015 HCML Share Option Scheme: Nil

6. Number of securities issued/allotted under scheme during period: (a) 2005 HCML Share Option Scheme: 12,562 ordinary shares of US$1 each

   (b) 2015 HCML Share Option Scheme: 112,500 ordinary shares of US$1 each

7. Balance under scheme not yet issued/allotted at end of the period: (a) 2005 HCML Share Option Scheme: 206,791 ordinary shares of US$1 each

   (b) 2015 HCML Share Option Scheme: 2,313,097 ordinary shares of US$1 each

8. Number and class of securities originally listed and the date of admission: (i) 2,560,606 ordinary shares of US$1 each admitted on June 26, 2007

   (ii) 1,000,000 ordinary shares of US$1 each admitted on June 20, 2016

   (iii) 1,425,597 ordinary shares of US$1 each admitted on April 27, 2018

9. Total number of securities in issue at the end of the period: 66,657,745 ordinary shares of US$1 each

Name of contact: Christian Hogg

Address of contact: Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong

Telephone number of contact: +852 2121 8200
About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 400 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

**Investor Enquiries**
Mark Lee, Senior Vice President, Corporate Finance & Development
David Dible, Citigate Dewe Rogerson
Xuan Yang, Solebury Trout
+852 2121 8200
+44 7967 566 919 (Mobile)
+1 (415) 971 9412 (Mobile)
david.dible@citigatedewerogerson.com
xyang@troutgroup.com

**Media Enquiries**
UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson
Americas – Brad Miles, Solebury Trout
Hong Kong & Asia ex-China – Joseph Chi Lo, Brunswick
Mainland China – Sam Shen, Edelman
+44 7973 611 888 (Mobile)
+1 (917) 570 7340 (Mobile)
+852 9850 5033 (Mobile)
+86 136 7179 1029 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
bmiles@troutgroup.com
jlo@brunswickgroup.com
yzhou@brunswickgroup.com
sam.shen@edelman.com

**Nominated Advisor**
Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited
+44 (20) 7886 2500